NASDAQ:BRNS Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis → America's #1 AI Dividend Stock Revealed (From The Oxford Club) (Ad) Free BRNS Stock Alerts $1.83 -0.08 (-4.19%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.79▼$1.9050-Day Range$1.83▼$3.3352-Week Range$1.64▼$5.10Volume7,672 shsAverage Volume17,342 shsMarket Capitalization$71.42 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Barinthus Biotherapeutics alerts: Email Address Barinthus Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside200.5% Upside$5.50 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.30) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector554th out of 915 stocksPharmaceutical Preparations Industry259th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingBarinthus Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBarinthus Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Barinthus Biotherapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently decreased by 36.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBarinthus Biotherapeutics does not currently pay a dividend.Dividend GrowthBarinthus Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRNS. Previous Next 2.5 News and Social Media Coverage News SentimentBarinthus Biotherapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Barinthus Biotherapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for BRNS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Barinthus Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Barinthus Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.20% of the stock of Barinthus Biotherapeutics is held by institutions.Read more about Barinthus Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Barinthus Biotherapeutics are expected to decrease in the coming year, from ($2.30) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Barinthus Biotherapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Barinthus Biotherapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBarinthus Biotherapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Barinthus Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubAmerica's #1 AI Dividend Stock RevealedIncome expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Barinthus Biotherapeutics Stock (NASDAQ:BRNS)Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Read More BRNS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRNS Stock News HeadlinesJune 15 at 3:50 AM | americanbankingnews.comBarclays Lowers Barinthus Biotherapeutics (NASDAQ:BRNS) Price Target to $3.00June 15 at 2:20 AM | americanbankingnews.comBarinthus Biotherapeutics' (BRNS) Outperform Rating Reaffirmed at William BlairJune 13 at 8:48 AM | americanbankingnews.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest UpdateJune 12 at 4:01 PM | globenewswire.comBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsJune 8, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)June 6, 2024 | globenewswire.comBarinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis BMay 13, 2024 | investorplace.comBRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024May 13, 2024 | globenewswire.comBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsMay 4, 2024 | finance.yahoo.comIncreases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)May 1, 2024 | globenewswire.comBarinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerApril 19, 2024 | markets.businessinsider.comInfection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed PerspectivesApril 18, 2024 | globenewswire.comBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) InfectionsApril 14, 2024 | seekingalpha.comBRNS Barinthus Biotherapeutics plcMarch 22, 2024 | finance.yahoo.comBarinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023March 20, 2024 | benzinga.comBarinthus Biotherapeutics: Q4 Earnings InsightsMarch 20, 2024 | globenewswire.comBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate DevelopmentsMarch 4, 2024 | finance.yahoo.comIndividual investors account for 48% of Barinthus Biotherapeutics plc's (NASDAQ:BRNS) ownership, while institutions account for 25%February 25, 2024 | benzinga.comBarinthus Biotherapeutics Stock (NASDAQ:BRNS) Dividends: History, Yield and DatesSee More Headlines Receive BRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BRNS Previous SymbolNASDAQ:BRNS CUSIPN/A CIK1828185 Webwww.barinthusbio.com Phone44-1865-818-808FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside+200.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,350,000.00 Net MarginsN/A Pretax Margin-21,958.09% Return on Equity-36.61% Return on Assets-31.75% Debt Debt-to-Equity RatioN/A Current Ratio11.15 Quick Ratio11.15 Sales & Book Value Annual Sales$334,000.00 Price / Sales213.86 Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book0.38Miscellaneous Outstanding Shares39,033,000Free Float35,910,000Market Cap$71.43 million OptionableN/A Beta-0.46 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. William J. Enright MBA (Age 62)CEO & Director Comp: $969.44kDr. Nadege Pelletier Ph.D. (Age 45)Chief Scientific Officer Comp: $593.48kMr. Graham Griffiths (Age 44)Chief Business Officer Comp: $522.23kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma Brown (Age 33)CFO & Company Secretary Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPGeoffrey LynnSenior Vice President of Synthetic ImmunotherapiesMore ExecutivesKey CompetitorsKamadaNASDAQ:KMDAMacroGenicsNASDAQ:MGNXEnanta PharmaceuticalsNASDAQ:ENTANature's Sunshine ProductsNASDAQ:NATRMersana TherapeuticsNASDAQ:MRSNView All CompetitorsInstitutional OwnershipBlueCrest Capital Management LtdBought 542,673 shares on 5/16/2024Ownership: 1.394%DC Funds LPBought 642,204 shares on 5/14/2024Ownership: 1.650%View All Institutional Transactions BRNS Stock Analysis - Frequently Asked Questions Should I buy or sell Barinthus Biotherapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Barinthus Biotherapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BRNS shares. View BRNS analyst ratings or view top-rated stocks. What is Barinthus Biotherapeutics' stock price target for 2024? 3 brokerages have issued 1 year price objectives for Barinthus Biotherapeutics' shares. Their BRNS share price targets range from $3.00 to $8.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 200.5% from the stock's current price. View analysts price targets for BRNS or view top-rated stocks among Wall Street analysts. How have BRNS shares performed in 2024? Barinthus Biotherapeutics' stock was trading at $3.69 on January 1st, 2024. Since then, BRNS shares have decreased by 50.4% and is now trading at $1.83. View the best growth stocks for 2024 here. Are investors shorting Barinthus Biotherapeutics? Barinthus Biotherapeutics saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 5,800 shares, a drop of 36.3% from the May 15th total of 9,100 shares. Based on an average daily volume of 23,500 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company's shares are short sold. View Barinthus Biotherapeutics' Short Interest. When is Barinthus Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our BRNS earnings forecast. How were Barinthus Biotherapeutics' earnings last quarter? Barinthus Biotherapeutics plc (NASDAQ:BRNS) announced its earnings results on Monday, May, 13th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.24. Who are Barinthus Biotherapeutics' major shareholders? Barinthus Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include DC Funds LP (1.65%) and BlueCrest Capital Management Ltd (1.39%). How do I buy shares of Barinthus Biotherapeutics? Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BRNS) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.